Blog Archives - Page 71 of 81 - NFCR

Blog

Cancer: There’s an App for That

Here’s a variety of smartphone applications created to specifically address the needs of the cancer community....

Read more

“System Mistrust” Interferes With Post-Surgery Breast Cancer Treatments

BALTIMORE — A study led by a Johns Hopkins Bloomberg School of Public Health researcher indicates nearly one-third of breast cancer surgery patients went against their doctor’s advice, choosing to not begin or complete adjuvant anti-cancer therapy. The primary factor: a general mistrust of the American healthcare system. Adjuvant therapy…...

Read more

Novel Cancer Genes Discovered Via New Statistical Model

LONDON — A new statistical model developed by scientists at the Francis Crick Institute revealed 27 novel genes thought to prevent cancer from forming, in an analysis of over 2000 tumors across 12 human cancer types. The findings could help create new cancer treatments that target these genes, and open…...

Read more

6 Tips for Staying Healthy During the Holidays

You can follow these simple tips for eating and living healthy this holiday season. Remember: Research links certain cancers to obesity....

Read more

7 Facts You Need to Know About Lung Cancer

With lung cancer affecting the lives of so many people, it’s important to understand the disease and what we can do to improve our chances of beating it....

Read more

NFCR Leads Delegation to Chinese BioMed Conference, Signs MOU with Host

The National Foundation for Cancer Research, led by Chairman Joseph F. Franlin and President Sujuan Ba, recruited a delegation of eight U.S. cancer technology start-ups for a successful exploratory mission to China. The companies—ArrayBio, Eutropics, Immix Biopharma, InterLeukin Therapeutics, International Cancer Impact Fund, InVaMet Therapeutics, Nonpareil Biotechnologies and Stromatis Pharma—were…...

Read more

Genetic Marker Can Help Focus Prostate Cancer Therapies

CLEVELAND, OH — Two studies conducted by the Cleveland Clinic revealed how a testosterone-related genetic abnormality can help predict individual patient responses to specific prostate cancer therapies. The studies, published in the October 12 issue of JAMA Oncology, suggest that men who inherit this variant would benefit from a personalized…...

Read more